Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points.
Assessment of the benefits of anti-diabetic drugs for type 2 diabetes requires analysis of composite end-points, taking HbA1c, bodyweight, hypoglycemia and other metabolic parameters into consideration; continuous, optimal glycemic control as well as bodyweight, blood pressure and lipid levels are critical to prevent micro- and macro-vascular complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now established as an important total treatment strategy for type 2 diabetes, exerting glucose-lowering effects with little hypoglycemia risk and also ameliorating bodyweight, blood pressure and lipid levels, which are therapeutic targets for prevention of complications of the disease. The available data strongly suggest only beneficial effects of GLP-1RAs; however, long-term evaluation of the relevant composite end-points including health-related quality of life and cost-effectiveness remain to be investigated in adequately powered, prospective, controlled clinical trials. In the meantime, healthcare professionals need to be scrupulously attentive for potential, rare adverse events in patients using GLP-1RAs.
Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital , Osaka , Japan.
Daisuke
D
Yabe
Hitoshi
H
Kuwata
Ryota
R
Usui
Takeshi
T
Kurose
Yutaka
Y
Seino
D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D011788:Quality of Life; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
GLP-1 receptor agonists; composite end-points; cost effectiveness; health-related quality of life; type 2 diabetes